Clinical trials: Patent Ductus Arteriosus (PDA)
Apnea of Prematurity, Preterm Birth
Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants
Intermittent episodes of hypoxemia and/or bradycardia, also defined as cardio-respiratory events (CRE) are very frequent in preterm infants and may result in transient hypoxia and hypoperfusion of target organs, with possible…
- Conditions
- Apnea of Prematurity, Preterm Birth, Patent Ductus Arteriosus, Hypoxia, Brain
- Trial name
- NCT04184245
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prematurity, Respiratory Distress Syndrome
Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants
Approval of surfactant by the FDA in 1989 for the treatment of Respiratory Distress Syndrome (RDS) in premature infants greatly improved survival rates.
- Conditions
- Prematurity, Respiratory Distress Syndrome, Patent Ductus Arteriosus
- Trial name
- CAST (NCT00767039)
- Testing
- Survanta (beractant), Curosurf (poractant)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Alan Fujii
Cardiovascular Diseases, Defect, Congenital Heart
Management of Patent Ductus in Premature Infants
To evaluate the effects (up to one year of age) of indomethacin on the clinical course of patent ductus arteriosus (PDA) in premature infants (24 hours old or less) and to assess the relative merits of indomethacin and surgery in…
- Conditions
- Cardiovascular Diseases, Defect, Congenital Heart, Ductus Arteriosus, Patent, Heart Diseases
- Trial name
- NCT00000494
- Testing
- indomethacin, surgery, cardiovascular
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Patent Ductus Arteriosus (PDA)
Nit-Occlud PDA Post-Approval Study
The Nit-Occlud PDA Post-Approval Study is designed to continue to evaluate the safety and effectiveness of the device in the post-approval phase.
- Trial name
- NCT02100683
- Testing
- PDA Coil
- Where
- 11 sites in United States
- Volunteers
- 184 people
- Sponsor
- PFM Medical, Inc
Patent Ductus Arteriosus
Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants
The purpose of this study is to determine oral paracetamol and ibuprofen efficacy and safety in relation to serum levels in closure of patent ductus arteriosus in preterm infants.
- Trial name
- NCT01544972
- Testing
- Oral paracetamol, Oral ibuprofen
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Patent Ductus Arteriosus
Do Elevated BNP Levels Predict Hemodynamically Significant PDAs
The purpose of this study is to determine if B type natriuretic peptide (BNP) levels can be used to predict a hemodynamically significant patent ductus arteriosus (PDA).
- Trial name
- NCT01497054
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Albany Medical College
Patent Ductus Arteriosus
Paracetamol and Patent Ductus Arteriosus (PDA)
The investigators propose that paracetamol will be similarly effective to ibuprofen in treating PDA in the premature neonate, with fewer side effects.
- Trial name
- NCT01291654
- Testing
- Paracetamol, NSAID, D5W
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Shaare Zedek Medical Center
Prematurity of Fetus, Patent Ductus Arteriosus
Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants
The purpose of this study is to examine the influence medical or surgical treatment for patent ductus arteriosus in preterm infants on cerebral and renal tissue oxygenation and on cardiac output.
- Trial name
- NCT01428180
- Testing
- Indomethacin, Surgical Ligation, Ibuprofen
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- University of Ulm
Ductus Arteriosus, Patent
Alternative Paracetamol Treatments for the Neonate With a hsPDA
Early targeted treatment of a hemodynamically significant patent ductus arteriosus (hsPDA) during the first week of life in preterm neonates is often recommended.
- Trial name
- NCT03604796
- Testing
- Rectal Solution, Intravenous Infusion
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Shaare Zedek Medical Center
Echocardiography, PDA
Echocardiography-guided Percutaneous Patent Ductus Arteriosus Closure
Since the first successful percutaneous closure under transoesophageal echocardiographic (TEE) guidance, many centres explored transcatheter procedures without fluoroscopy.
- Trial name
- NCT05321849
- Testing
- Echocardiography guide
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Patent Ductus Arteriosus, Duct-dependent Cyanotic Congenital Heart Disease
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
This is a pilot study on feasibility, efficacy and safety of IBS ® for implantation in the PDA in duct-dependent cyanotic CHD, and its objective is to investigate the feasibility, safety and efficacy of iron resorbable stent…
- Trial name
- NCT04291222
- Testing
- Iron biocorrodable coronary scaffold system
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Patent Ductus Arteriosus After Premature Birth, Hyper Bilirubinemia
The Effects of Phototherapy in Preterm Infants Pda
The study was designed to assess whether chest shielding during phototherapy reduces the incidence of PDA, as assessed by serial echocardiographic examinations, in a population of extremely preterm infants born at lower 30 week…
- Trial name
- NCT03675425
- Testing
- Group 1: non chest shielding, Group 2: chest shielding
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Patent Ductus Arteriosus
Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants
To determine whether oral or intravenous ibuprofen has a better or same efficacy and tolerance in closure of patent ductus arteriosis in extremely-low-birth-weight preterm infants.
- Trial name
- NCT01261117
- Testing
- oral ibuprofen
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
PDA
NIRS in PDA VLBW Infants
Aim of study: To conduct an observational study to collect cerebral and renal perfusion data through NIRS before and after treatment of PDA by medication or by PDA ligation.
- Trial name
- NCT02396004
- Testing
- Near Infrared Red Spectroscopy (NIRS)
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore General Hospital
Patent Ductus Arteriosus
Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA)
The aim of current study is to evaluate the efficacy and safety of oral Ibuprofen in term 20-28 days old newborn referred to Bandarabbas children' hospital in 2011.
- Trial name
- NCT01511887
- Testing
- Oral Ibuprofen
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Hormozgan University of Medical Sciences
Patent Ductus Arteriosus
Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed
Patent ductus arteriosus (PDA) is common in preterm infants. In the presence of a large PDA, significant systemic to pulmonary shunting occurs, which may results in pulmonary hyperperfusion and systemic hypoperfusion.
- Trial name
- NCT03723889
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Patent Foramen Ovale, Atrial Septal Defect
Lifetech CeraFlex™ Post-Market Surveillance Study
The purpose of this multi-center, non-interventional, prospective, post-market clinical study is to collect real world data on patient outcomes and evaluate the procedural success and performance of the Lifetech CeraFlex™…
- Conditions
- Patent Foramen Ovale, Atrial Septal Defect, Patent Ductus Arteriosus
- Trial name
- NCT02621528
- Testing
- CeraFlex
- Where
- 7 sites in France, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Patency of the Ductus Arteriosus, Acetaminophen
Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen
TREOCAPA is a Phase II/III European Multicentre study concerning the prophylactic treatment by Acetaminophen of extremely preterm infant during the first five days after birth.
- Conditions
- Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity
- Trial name
- TREOCAPA (NCT04459117)
- Testing
- Acetaminophen, NACL 0.9%
- Where
- 36 sites in Belgium, Denmark and 10 more
- Volunteers
- 804 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Patent Ductus Arteriosus
Paracetamol Versus Ibuprofen for PDA Closure
Comparison between the safety and efficacy of oral paracetamol and oral ibuprofen in treatment of Patent Ductus Arteriosus (PDA) in premature infants
- Trial name
- NCT03265782
- Testing
- ibuprofen, paracetamol
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Patent Ductus Arteriosus, Prematurity
Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure
The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of…
- Trial name
- NCT00833365
- Testing
- Ibuprofen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Utah